Phased Review and the Cancer Medicines Pathfinder: A Faster Route to a Centralised Opinion

In July 2026 EMA announced a phased (rolling) review of daraxonrasib for metastatic pancreatic cancer. In October the CHMP recommended it as Rasonque. The case shows how the Cancer Medicines Pathfinder and phased review can compress the path to an opinion.

What phased review is

Under a phased review, the CHMP assesses data in stages as they become available, rather than waiting for a complete application. EMA describes the parts as quality, nonclinical and clinical data, reviewed before the full marketing authorisation application is submitted.

The standards do not change. Medicines under phased review must meet the same quality, safety and efficacy requirements as any other medicine, and EMA states the overall timeline cannot be predicted in advance, only expected to be shorter than a regular evaluation.

The Cancer Medicines Pathfinder

Daraxonrasib was recognised as a high-priority medicine under EMA’s Cancer Medicines Pathfinder because of its potential to address a high unmet medical need. That recognition supported eligibility for a centralised application. EMA has said it will decide on other candidates case by case, looking at unmet need and public health interest.

Practical implications for sponsors

  • Early dialogue is essential. Eligibility depends on a strong rationale, typically robust phase 3 data against a relevant comparator.
  • Modules must mature in sequence. Quality data cannot trail the clinical package if the stages are to run smoothly.
  • Downstream steps still need planning. A faster opinion brings forward pricing, reimbursement and HTA work, including joint clinical assessment preparation where applicable.

Not a shortcut on evidence

Speed comes from the way data are reviewed, not from lower expectations. Companies should expect the same level of scrutiny, with less time to resolve weaknesses.

How PQRA helps

PQRA helps oncology and specialty sponsors assess eligibility for expedited pathways, structure rolling submissions, and align regulatory timelines with Greek access planning so a faster opinion translates into faster patient access.

Contact PQRA to discuss your situation

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *